EXHIBIT 99.01
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com | ![]() |
Press Release | |
FIRST QUARTER 2008 RESULTS DATE NOTIFICATION
25 April 2008
Basingstoke, UK and Philadelphia, US – April 16, 2008 – Shire plc (LSE: SHP, NASDAQ: SHPGY) will announce first quarter 2008 earnings on Friday 25 April 2008.
Results press release will be issued at: | 12:00 BST / 07:00 EDT |
Investor conference call time: | 14:00 BST / 09:00 EDT |
Live conference call for investors:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:00 BST/9:00 EDT.
Please RSVP ssalah@shire.com (T: +44 (0)1256 894 160) for this conference call.
The details of the live conference call are as follows:
UK and International dial in | +44 (0)2030234496 |
US dial in | 1 8669665335 |
Password/Conf ID | Shire |
Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.
Registered in England 5492592 Registered Office as above
Replay:
A replay of the presentation will be available for two weeks. Details are as follows:
UK and International dial in | 44-20-8196-1998 |
US dial in | 1-866-583-1035 |
Pin code | 3008632# |
Webcast replay | www.shire.com, in the investors section |
For further information please contact:
Investor Relations | Souheil Salah (Rest of the World) | +44 1256 894 160 |
Emily Berish (North America) | +1 484 595 8546 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com
Registered in England 5492592 Registered Office as above